Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled period are to evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD, and to evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD. The primary objective of the long-term extension period is to evaluate the long-term safety and tolerability of BIIB092 in participants with MCI due to AD or with mild AD.

Key facts

Study ID
NCT03352557
Run by
Biogen
People needed
654
Starts
2018-05-03
Expected to finish
2021-08-30
Last updated by the study team
2022-11-08

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.